H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Krystal Biotech (NASDAQ:KRYS) Inc on Friday, setting a price target of $84, which is approximately 28.74% above the present share price of $65.25.
Pantginis expects Krystal Biotech Inc to post earnings per share (EPS) of -$0.49 for the first quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Krystal Biotech, with an average price target of $92.
The analysts price targets range from a high of $100 to a low of $84.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$9.68 million. The company's market cap is $1.25 billion.
According to TipRanks.com, H.C. Wainwright analyst Joseph Pantginis is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 36.5% and a 64.80% success rate.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.